brentuximab,doxorubicin hydrochloride,dacarbazine,filgrastim,pegfilgrastim,nivolumab,vinblastine sulfate
seagen,amgen,bms
['nivolumab', 'nivo', 's1826']
plenary - swog s1826
stage 3/4 chl: 1l nivolumab-avd vs bv-avd. 1 year pfs: 94% vs 86%, hr: 0.48.
only &lt;1% received rt - better long term outcomes. new soc for patients age 12+!!!
#asco23 
Medical Oncologist. Chief of Hem/Onc, PD of hem/onc fellowship, Dr Peter White Endowed Professor, & Associate Professor at The University of Toledo.